Chemistry:Radretumab
From HandWiki
Short description: Monoclonal antibody
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | fibronectin |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| | |
Radretumab is an antineoplastic. Philogen, a pharmaceutical company specializing in antibody-drug conjugates, is developing it as a conjugate of Iodine-131 to an antibody which binds to fibronectin extra domain-B for treatment of Hodgkin lymphoma.[1][2][3]
References
- ↑ "Radretumab (L19-131I)". Philogen. http://www.philogen.com/en/products/pipeline/radretumab-l19-131i_13.html.
- ↑ World Health Organization (2010). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 104". WHO Drug Information 24 (4). https://www.who.int/medicines/publications/druginformation/innlists/Final_PL104.pdf.
- ↑ "Radioimmunotherapy with radretumab in patients with relapsed hematologic malignancies". Journal of Nuclear Medicine 53 (6): 922–7. June 2012. doi:10.2967/jnumed.111.101006. PMID 22577235.
